# A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

> **NCT07702890** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gubra A/S** · enrollment: 188 (estimated)

## Conditions studied

- Obesity
- Type 2 Diabetes

## Interventions

- **DRUG:** GUB-UCN2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07702890
- **Lead sponsor:** Gubra A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702890, "A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07702890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*